Abbott Abbokinase Use Should Be Limited Due To Infection Risks From Donors

Abbott's Abbokinase should be limited to patients who specifically require the thrombolytic agent, FDA's Center for Biologics Evaluation & Research declared in a Jan. 25 letter to healthcare providers.